Olsitri (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine and hydrochlorothiazide, the active ingredients in Olsitri, are a combination antihypertensive presented as a tablet for oral use. It treats essential hypertension in adult patients.

GNH USA supplies Olsitri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olsitri, a combination antihypertensive, is indicated for conditions related to elevated blood pressure.

Essential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. Isolated systolic hypertension: reduces high systolic readings in older adults. Hypertension requiring triple therapy: provides three complementary mechanisms for patients not controlled on single or dual agents.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema, especially of the ankles - Flushing or warmth sensation - Fatigue or mild weakness - Increased urinary frequency

Serious or Rare Side Effects: - Severe hypotension or syncope - Electrolyte disturbances such as hyperkalemia, hyponatremia, or hypokalemia - Acute kidney injury or worsening renal function - Angioedema or severe allergic reactions - Liver enzyme elevation or hepatitis - Blood dyscrasias such as leukopenia or thrombocytopenia

Before initiating Olsitri, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels due to the thiazide component. - Hepatic impairment: use with caution in patients with liver disease as metabolism may be altered. - Hypersensitivity: discontinue if signs of rash, angioedema, or anaphylaxis appear. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olsitri may interact with several medicines that affect blood pressure, electrolytes, or drug metabolism.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia. - Dual renin‑angiotensin system blockade (ACE inhibitor or another ARB): may cause severe hypotension and kidney injury. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): raise amlodipine plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, ACE inhibitors): additive blood‑pressure lowering. - Lithium: thiazide component can raise lithium concentrations. - Digoxin: possible increase in serum digoxin levels. - Additional thiazide diuretics: heightened electrolyte disturbances. - Alcohol: may enhance hypotensive effect.